OCRELIZUMAB (OCREVUS) prior authorization at Regence
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Regence reviews OCRELIZUMAB (OCREVUS) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody [EPC]. The FDA-approved indication (2017) is INJECTABLE. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Regence's medical policy URL referenced in the cover letter
Regence's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Cross-state coordination for multi-state members (OR/WA/ID/UT)
- Step therapy via Prime Therapeutics
- Behavioral health network adequacy
- Specialty drug PA
If the PA is denied
Regence gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.regence.com/provider) with the same packet plus a peer-reviewed citation supporting OCRELIZUMAB (OCREVUS)for the patient's indication.
Contact Regence
- Provider portal: https://www.regence.com/provider
Frequently asked questions
What documentation does Regence need for OCRELIZUMAB (OCREVUS) prior auth?
Regence's typical PA packet for OCRELIZUMAB (OCREVUS): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Regence?
Standard OCRELIZUMAB (OCREVUS) PA decisions at Regence: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Regence most often reject OCRELIZUMAB (OCREVUS) for?
Across Regence's book the common rejection patterns include: Cross-state coordination for multi-state members (OR/WA/ID/UT); Step therapy via Prime Therapeutics; Behavioral health network adequacy. For OCRELIZUMAB (OCREVUS) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Regence on OCRELIZUMAB (OCREVUS)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the OCRELIZUMAB (OCREVUS) PA packet
Open ApprovalHelp — generate a OCRELIZUMAB (OCREVUS) prior-auth packet tailored to Regence's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com